Browse

Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout

In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”